Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

9amHealth vs AM Rx

By GLP-1 ScorecardUpdated

9amHealth
Site position #103

Higher grade

AM Rx
Site position #533

Lower grade

Score comparison

9amHealth has the higher recorded score — 71.3/100 to 49.9/100.

9amHealth grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. 9amHealth combines weight, diabetes and heart-health care with branded prescribing, nutrition support and insurance navigation. Confirm program access, care fees and pharmacy costs separately.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost value9amHealth +17
68
51
Dose & formulationEven
65
65
Clinical oversight9amHealth +47
88
41
Labs & monitoring9amHealth +25
74
49
Fulfillment9amHealth +10
68
58
Contract terms9amHealth +35
55
20
9amHealth · top barAM Rx · bottom bar

The numbers

Swipe or scroll to compare both providers.

Metric9amHealthAM Rx
WeighScore71.3/10049.9/100
GradeCC
Site position#103#533
SemaglutideNot disclosed (brand-name; current medication quote required)$151/mo (quarterly plan, plus a separate fee, compounded)
TirzepatideNot disclosedNot disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessYesYes
Oral / sublingualNot confirmedNot confirmed
9amHealth

Site position #103 · C

Strengths

  • Care team includes physicians, pharmacists and registered dietitians
  • Individual program describes continuing medication management, follow-up and nutrition support
  • Branded GLP-1 options are considered alongside medical history, tests and insurance coverage
  • Home blood draw where available or a patient service center, with care-team review
  • Separate individual, employer and health-plan programs offer different access routes

What to consider

  • Current care and medication charges need a selected written quote; older campaign prices conflict
  • The advertised $199 Wegovy introduction expired June 30, 2025
  • Care, medication and lab costs depend on the selected program and benefits; obtain an itemized quote
  • Clinical eligibility and the applicable benefit formulary determine prescription access
  • The reviewed public pages do not establish current cancellation, refund or state-by-state terms
AM Rx

Site position #533 · C

FDAWarning letter issued to FitRX, LLC dba AM RX in June 2026. See the FDA warning-letter database.

Strengths

  • Insurance coordination for brand-name GLP-1s — as low as $25/mo
  • All four major brand-name GLP-1s available (Ozempic, Wegovy, Zepbound, Mounjaro)
  • HSA and FSA accepted
  • Video visits available with providers averaging 10+ years' experience
  • Compounded semaglutide from $151/mo on the quarterly plan

What to consider

  • Active FTC/DOJ lawsuit over deceptive billing and subscription practices
  • Novo Nordisk false-advertising lawsuit (Aug 2025)
  • Parent company Zealthy holds a BBB D- rating with 2,370+ complaints
  • Trustpilot 2.0/5, with 85% one-star reviews citing billing disputes and unreachable support
  • FDA issued FitRX, LLC dba AM RX a warning letter in June 2026; the letter is public in FDA's warning-letter database

Featured provider

CoreAge Rx

CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.

Commercial relationships affect this placement. The score comparison above is separate.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard